159 results about "Neutral lipid" patented technology

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).

The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R₁ and R₂ are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R₃ and R₄ are independently lower alkyl or R₃ and R₄ can be taken together to form an optionally substituted heterocyclic ring. In one embodiment, R₁ and R₂ are independently selected from oleoyl, pamitoyl, steroyl, linoleyl and R₃ and R₄ are methyl. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO₂ or CO₂ plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO₂ in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Methods for selective extraction and fractionation of algal lipids and algal products are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which enable efficient separation of algal components. Among these components are neutral lipids synthesized by algae, which are extracted by the methods disclosed herein for the production of renewable fuels.

A method for producing biofuels along with valuable food and neutraceutical products is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, extracting neutral lipids along with carotenoids and chlorophylls from the algal biomass, and separation of the carotenoids and chlorophylls using adsorption or membrane diafiltration or other methods. The remaining neutral lipids are esterified with a catalyst in the presence of an alcohol. The method also includes separating a water soluble fraction comprising glycerin from a water insoluble fraction comprising fuel esters and distilling the fuel esters under vacuum to obtain a C16 or shorter fuel esters fraction, a C16 or longer fuel ester fraction, and a residue comprising omega-3 fatty acids esters and remaining carotenoids. The method further includes hydrogenating and deoxygenating at least one of (i) the C16 or shorter fuel esters to obtain a jet fuel blend stock and (ii) the C16 or longer fuel esters to obtain a diesel blend stock.

Disclosed are multilayered liposomes for transdermal absorption and a method of preparing the liposomes. The multilayered liposomes are prepared using a mixture of oil-phase components comprising squalane, sterols, ceramides, neutral lipids or oils, fatty acids and lecithins, is 200 to 5000 nm in particle size, and is capable of entrapping a physiologically active substance. The multilayered liposomes entrap a larger amount of a physiologically active substance and are structurally stable when encapsulating the physiologically active substance, compared to unilamellar liposomes. Also, they are prepared by a simple and cost-effective process not using a high-pressure homogenizer but using a general homo mixer. Further, since the multilayered liposomes are prepared in a larger size than the intercellular spaces in the stratum corneum, they overcome the tension of surrounding cells when passing through the intercellular spaces and are thus able to penetrate into the dermal layer, compared to nano-sized unilamellar liposomes. Thus, the multilayered liposomes are useful for enhancing the transdermal absorption of physiologically active substances.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

A method for separating polar lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting polar lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal polar lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. These polar lipids are high value products which can be used as surfactants, detergents, and food additives. Neutral lipids remaining in the algal biomass after extraction of polar lipids can be used to generate renewable fuels.

A method for producing biofuels is provided. A method of making biofuels includes dewatering substantially intact algal cells to make an algal biomass, sequentially adding solvent sets to the algal biomass, and sequentially separating solid biomass fractions from liquid fractions to arrive at a liquid fraction comprising neutral lipids. The method also includes esterifying the neutral lipids, separating a water miscible fraction comprising glycerin from a water immiscible fraction comprising fuel esters, carotenoids, and omega-3 fatty acids. The method also includes obtaining a C16 or shorter fuel esters fraction, a C16 or longer fuel ester fraction, and a residue comprising carotenoids and omega-3 fatty acids. The method includes hydrogenating and deoxygenating at least one of (i) the C16 or shorter fuel esters to obtain a jet fuel blend stock and (ii) the C16 or longer fuel esters to obtain a diesel blend stock.

Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.

The present invention relates to a method for introducing one or more antisense oligonucleotides into one or more eucaryotic cells using one or more lipid formulations comprising one or more cationic lipids of Formula I and optionally at least one neutral lipid. In particular, the present invention relates to a method for introducing one or more antisense oligonucleotides into one or more eucaryotic cells using a lipid formulation comprising dimethyldioctadecylammonium bromide (DDAB) and at least one neutral lipid, especially dioleylphosphatidylethanolamine (DOPE). The invention also relates to kits for carrying out the invention, compositions for carrying out the invention, and compositions formed while carrying out the invention. Further, the present invention relates to a method for inhibiting or preventing cell growth or proliferation, and a method for inhibiting or preventing expression of one or more proteins.

Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.

A method for separating neutral lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting neutral lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal neutral lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. The neutral lipids are removed after first removing a polar lipid fraction and a protein fraction. These neutral lipids can be used to generate renewable fuels as well as food products and supplements.

A method for separating polar lipids from plant material, in particular, intact algal cells, using an amphipathic solvent set and a hydrophobic solvent set. Some embodiments include dewatering intact algal cells and then extracting polar lipids from the algal cells. The methods provide for single and multistep extraction processes which allow for efficient separation of algal polar lipids from a wet algal biomass while avoiding emulsification of extraction mixtures. These polar lipids are high value products which can be used as surfactants, detergents, and food additives. Neutral lipids remaining in the algal biomass after extraction of polar lipids can be used to generate renewable fuels.

The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell via a neutral (non-charged) liposome. These methods may be used to treat a disease, such as cancer.

The invention discloses a novel cationic liposome, a cationic liposome nucleic acid pharmaceutical preparation having the same as well as a preparation method and application thereof. The cationic liposome comprises cationic lipid, assisted lipo, polycarboxyl betaine lipid molecule and a freezing protective agent. The cationic liposome nucleic acid pharmaceutical preparation comprises cationic liposome modified by neutral lipid of polycarboxyl betaine and nucleic acid pharmaceutical preparation working solution. According to the cationic liposome, the defects of high toxicity, bad blood stability and low transfection efficiency are overcome and the pharmaceutical effects of the nucleic acid drugs are effectively improved; and at the same time, as the preparation is undisturbed by blood serum during the use, the operations in the experiment and the treatment are simplified.